The Short-Term Technical score evaluates a stock's trading pattern over the past month and is most useful to short-term stock and option traders. The stock’s 5-day price performance is 3.11%, and it has moved by 7.70% in 30 days. SIC: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) 611 GATEWAY BLVD SOUTH SAN FRANCISCO, CA 94080. OTCIQ. View a stock's price, volume, volatility and other statistics, as well as a price chart, news, performance vs. peers and a company profile. IQ. Barron's also provides information on historical stock ratings, … Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of 7.53% and -50.60%, respectively, for the quarter ended March 2021. View which stocks have been most impacted by COVID-19. Atara Biotherapeutics has a 1 year low of $4.52 and a 1 year high of $28.20. Atara Biotherapeutics Inc. has some key milestones lined up for this year, making it a stock worth watching.Atara is focused on developing off-the-shelf, allogeneic T-cell immunotherapies for patients … View Atara Biotherapeutics stock trends here About ATRA Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which pioneers the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. Is Atara Biotherapeutics, … All of the shares in the proposed offering will be sold by Atara Biotherapeutics. ... or Atara Biotherapeutics? About Atara Biotherapeutics, Inc. Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, today announced that it has commenced an underwritten public offering of $150,000,000 of shares of its common stock. Atara Biotherapeutics stock price target cut to $16 from $23 at Goldman Sachs MarketWatch. The following is a brief description of each matter voted upon at the Annual Meeting, as well as the number of votes cast for or against each matter and the number of abstentions and broker non … Atara Biotherapeutics, Inc. (ATRA) is making a move down in the market today. Atara Biotherapeutics (NASDAQ:ATRA) was upgraded by stock analysts at JPMorgan Chase & Co. from a “neutral” rating to an “overweight” rating in a research note issued on Wednesday, Benzinga reports. Atara Biotherapeutics, Inc. Common Stock, also called Atara Biotherapeutics, is an allogeneic T-cell immunotherapy company, which pioneers the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. Atara Biotherapeutics Inc (ATRA) stock is trading at $19.63 as of 12:39 PM on Tuesday, Feb 2, a rise of $0.76, or 4.06% from the previous closing price of $18.86. Volume today is light. Free real-time prices, trades, and chat. Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. Get Stock & Bond Quotes, Trade Prices, Charts, Financials and Company News & Information for OTCQX, OTCQB and Pink Securities. The Fly team scours all sources of company news, from mainstream to cutting edge,then filters out the noise to deliver shortform stories consisting of only market moving content. Atara Biotherapeutics, Inc. (ATRA) is gaining in the market today. The company’s stock price has collected -4.39% of loss in the last five trading sessions. Atara Biotherapeutics Inc. (NASDAQ:ATRA) went down by -0.08% from its latest closing price compared to the recent 1-year high of $28.20. Click here now. (ATRA) SOUTH SAN FRANCISCO, Calif. (AP) _ Atara Biotherapeutics Inc. (ATRA) on Wednesday reported a loss of $76.9 million in its second quarter. The analysts price targets range from a … Thursday, Apr 20, 2017. With Atara Biotherapeutics stock trading at $13.91 per share, the total value of Atara Biotherapeutics stock (market capitalization) is $1.16B. Atara Biotherapeutics Inc. Blog. Atara … Atara Biotherapeutics Inc. Stock Price, News and Company Updates. ... Latest News All Times Eastern. Get Atara Biotherapeutics alerts: ATRA opened at $19.63 on Wednesday. ATRA has risen $0.56 from the previous closing price of $16.90 on volume of 572,058 shares. Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which pioneers the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. 5Y. Atara Biotherapeutics, Inc. Common Stock (ATRA) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. The stock options have a ten-year term and an exercise price of $14.05 per share, equal to the per share closing price of Atara’s common stock as reported by Nasdaq on May 3, 2021. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven … ATRA lost -$4.15 per share the over the last 12 months. Goldman Sachs has lost confidence in Atara Biotherapeutics, downgrading the stock to Sell from Neutral on Friday. The Atara Biotherapeutics stock price fell by -1.85% on the last day (Tuesday, 8th Jun 2021) from $14.06 to $13.80.During the day the stock fluctuated 6.48% from a day low at $13.42 to a day high of $14.29.The price has fallen in 6 of the last 10 days, but is still up by 1.55% over the past 2 weeks. What's Happening With Atara Biotherapeutics Inc Stock Today? All of the shares in the proposed offering will be sold by Atara Biotherapeutics. Latest Share Price and Events Stable Share Price : ATRA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week. Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of an aggregate of 140,861 restricted stock units of Atara… Explore commentary on Atara Biotherapeutics … The brokerage currently has a $29.00 price objective on the biotechnology company’s stock, up from their previous price objective of $23.00. ATRA Stock Message Board for Investors. Thinking about buying stock in Clovis Oncology, Ashford Hospitality Trust, Atara Biotherapeutics, Sorrento Therapeutics, or Vertex Energy? Get news for Nasdaq companies quoted on the stock market, press releases, financial disclosures and multimedia content, for investment community, individual investors and the general public. Latest Share Price and Events Stable Share Price : ATRA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week. Atara Biotherapeutics, Inc. is a leading allogeneic T-cell immunotherapy company pioneering the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases.Leveraging our novel allogeneic EBV T-cell platform, Atara intends to deliver treatments to patients with high unmet medical need. The stock options have a ten-year term and an exercise price of $17.10 per share, equal to the per share closing price of Atara’s common stock as reported by Nasdaq on March 1, 2021. View today's stock price, news and analysis for Atara Biotherapeutics Inc. (ATRA). also delivers off-the-shelf treatments to patients with high unmet medical need. Atara Biotherapeutics to Announce First Quarter 2021 Financial Results on Tuesday, May 4, 2021. Atara Biotherapeutics Inc. [NASDAQ: ATRA] traded at a low on 01/15/21, posting a -1.27 loss after which it closed the day’ session at $18.61. Atara Biotherapeutics' stock was trading at $9.96 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). The stock’s 50 day simple moving average is $22.40 and its … Amarin and Atara Biotherapeutics could both be diamonds in the rough. ATRA earnings call for the period ending December 31, 2019. These two cancer stocks are trading at a pittance compared to their long-term value propositions. ATRA earnings call for the period ending September 30, 2019. Atara's shares have collapsed this year. On April 11, 2018, Atara Biotherapeutics stock broke out of the symmetrical triangle, and a powerful move toward higher prices followed. Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, … Over the past year the S&P 500 has risen 64.84% while ATRA has risen 184.36%. Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including … Free forex prices, toplists, indices and lots more. ATRA News: Amended Statement of Ownership (sc 13g/a) 02/16/2021 … Thursday, April 20, 2017. Get Atara Biotherapeutics Inc (AT2-FF:Frankfurt Stock Exchange) real-time stock quotes, news, price and financial information from CNBC. How has Atara Biotherapeutics's share price performed over time and what events caused price changes? Atara Biotherapeutics news and ATRA price. Atara Biotherapeutics Inc operates in the United States healthcare sector. Get Atara Biotherapeutics Inc (ATRA:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. The share float percentage for the stock currently stands at 106.05%. Get today's Atara Biotherapeutics Inc stock news. If the last five payouts show limited variability, we estimate future payouts equal to the most … More Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease, today reported the grant of an aggregate of 229,931 restricted stock units of Atara’s common stock … For ETFs and Mutual Funds, return of capital and capital gains distributions are not included. News provided by. The stock has traded between $19.01 and $19.90 so far today. 05:16 PM ET. Free real-time prices, trades, and chat. Atara Biotherapeutics shares rise on MS drug study results MarketWatch. Atara Biotherapeutics (ATRA) stock price, charts, trades & the US's most popular discussion forums. The Investor Relations website contains information about Nasdaq, Inc.'s business for stockholders, potential investors, and financial analysts. 5 Beaten-Down Biotech Stocks Set to Rebound in 2020. The stock was sold at an average price of $14.06, for a total transaction of $81,829.20. ATRA News: Amended Statement of Ownership (sc 13g/a) 02/16/2021 04:38:44 PM. On April 11, 2018, Atara Biotherapeutics stock broke out of the symmetrical triangle, and a powerful move toward higher prices followed. On June 8, 2021, Atara Biotherapeutics, Inc. (the "Company") held its 2021 Annual Meeting of Stockholders (the "Annual Meeting"). 02-16 sec.gov - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. Atara Biotherapeutics Inc Change company Symbol … Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, today announced that it has commenced an underwritten public offering of $150,000,000 of shares of its common stock. Dec-18-19 07:59AM. Barron's also provides information on historical stock ratings, … When it comes to biotech companies, there are quite a few factors that have the potential to generate … Stock analysis for Atara Biotherapeutics Inc (ATRA:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Since then, ATRA shares have increased by 44.7% and is now trading at $14.41. Atara Biotherapeutics (ATRA) stock price, charts, trades & the US's most popular discussion forums. On Wednesday, Atara Biotherapeutics earned a positive adjustment to its Relative Strength (RS) Rating, from 66 to 74. The stock options have a ten-year term and an exercise price of $13.24 per share, equal to the per share closing price of Atara’s common stock as reported by Nasdaq on May 10, 2021. View the latest Atara Biotherapeutics Inc. (ATRA) stock price, news, historical charts, analyst ratings and financial information from WSJ. In connection with the proposed offering, Atara Biotherapeutics expects to grant the underwriters a 30-day option to purchase up to an additional $18,750,000 of shares of its common stock … Atara Biotherapeutics, Inc. (NASDAQ:ATRA) CFO Utpal Koppikar sold 5,820 shares of Atara Biotherapeutics stock in a transaction dated Tuesday, June 8th. Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its … ATRA News: Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results on Monday, March 1, 2021. The stock, one that is focused on the biotechnology sector, is presently trading at $13.52 after climbing 11.18% so far in today’s session. Thinking about buying stock in Heron Therapeutics, Casper Sleep, Evolus, Xeris Pharmaceuticals, or Atara Biotherapeutics? H.C. Wainwright have made an estimate for Atara Biotherapeutics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on November 10, 2020. ATRA - Atara Biotherapeutics, Inc. About. The stock options have a ten-year term and an exercise price of $14.05 per share, equal to the per share closing price of Atara’s common stock as reported by Nasdaq on May 3, 2021. We cover the latest Atara Biotherapeutics Inc headlines and breaking news impacting Atara Biotherapeutics Inc stock performance. ... or Atara Biotherapeutics? IQ. Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease, today reported the grant of an aggregate of 52,019 restricted stock units of Atara’s common stock … Negative monthly dynamics of the instrument is expected with 11.835% volatility is expected.. Pessimistic forecast: 9.81 Optimistic: 11.13 Atara Biotherapeutics stock forecast for Feb 2024. In depth view into ATRA (Atara Biotherapeutics) stock including the latest price, news, dividend history, earnings information and financials. Atara is providing this information in accordance with Nasdaq Listing Rule 5635 (c) (4). Get the hottest stocks to trade every day before the market opens 100% free. If we look at who the major shareholders are, we find that insiders hold 0.49% of Atara Biotherapeutics Inc. shares while 105.53% of the shares are in the hands of institutional holders. Atara Biotherapeutics to Announce First Quarter 2021 Financial Results on Tuesday, May 4, 2021 Provided by Business Wire Apr 27, 2021 9:51 PM UTC Business Wire Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop treatments for patients with severe diseases, including solid tumors, hematologic cancers and autoimmune disease, today announced the Company will release second quarter 2020 financial … On receiving your correspondence, Atara Biotherapeutics, Inc. is likely to request evidence of your identity, to ensure your Personal Information and information connected with it is not provided to anyone other than you. PR Newswire 01/27 09:31 ET Atara Biotherapeutics to Present Data at the 2021 Transplantation & Cellular Therapy Meeting Digital Experience Atara Biotherapeutics, Inc. ... today reported the grant of an aggregate of 140,861 restricted stock units of Atara’s common stock to 28 newly hired employees and stock … By directing users to the below third-party websites, Stash is not suggesting any endorsement, relationship, affiliation with … Atara Biotherapeutics presents long-term OS data from Phase 2 Tab-cel studies 02/08/21 Atara Biotherapeutics to present tabelecleucel data at ASTCT meeting 01/04/21 Atara Biotherapeutics provides update on BLA submission for tab-cel 12/07/20 Atara presents evaluation of CAR T Cell Therapy ATA3219 at ASH also delivers off-the-shelf … Message Board Total Posts: 68 ... Atara Biotherapeutics stock trades higher after Q3 earnings. Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, today announced that it has commenced an underwritten public offering of $150,000,000 of shares of its common stock. Atara Biotherapeutics stock forecast for Jan 2024. Data as of … Atara is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4). Thursday, September 15, 2016. What happened. In connection with the offering, Atara Biotherapeutics has granted the underwriters a 30-day option to purchase up to an additional 2,325,000 shares of its common stock at the public offering price, less the underwriting discounts and commissions. Press Release reported on 04/27/21 that Atara Biotherapeutics to Announce First Quarter 2021 Financial Results on Tuesday, May 4, 2021 Atara Biotherapeutics, Inc. Common Stock, also called Atara Biotherapeutics, is an allogeneic T-cell immunotherapy company, which pioneers the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. Market Activity. View real-time stock prices and stock quotes for a full financial overview. 10 analysts have issued 12 month price objectives for Atara Biotherapeutics' shares. Their predictions range from $9.00 to $70.00. On average, they anticipate Atara Biotherapeutics' share price to reach $31.00 in the next year. This suggests a possible upside of 146.8% from the stock's current price. ATRA News: Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results on Monday, March 1, 2021. Real time Atara Biotherapeutics (ATRA) stock price quote, stock graph, news & analysis. Atara Biotherapeutics (ATRA) stock price, charts, trades & the US's most popular discussion forums. Find the latest news headlines from Atara Biotherapeutics, Inc. Common Stock (ATRA) at Nasdaq.com. Headline News: Wed, 19 May 2021 Would Shareholders Who Purchased Atara Biotherapeutics' (NASDAQ:ATRA) Stock Three Years Be Happy With The Share price Today? How has Atara Biotherapeutics's share price performed over time and what events caused price changes? About Atara Biotherapeutics, Inc. Atara Biotherapeutics, Inc. (@Atarabio) is a pioneer in T-cell immunotherapy leveraging its novel allogeneic … Atara Biotherapeutics News: This is the News-site for the company Atara Biotherapeutics on Markets Insider. Atara Biotherapeutics Inc. (NASDAQ:ATRA) went down by -2.12% from its latest closing price compared to the recent 1-year high of $28.20. ... Look at this underappreciated sector for stock … Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to … Free forex prices, toplists, indices and lots more. ATRA News: Amended Statement of Ownership (sc 13g/a) 02/16/2021 04:16:50 PM. Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which pioneers the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. Over the last year, Atara Biotherapeutics, Inc.’s stock price has increased by 20.64%. Atara Biotherapeutics Inc. provides health care services. Atara Biotherapeutics Inc. [NASDAQ: ATRA] traded at a low on 01/15/21, posting a -1.27 loss after which it closed the day’ session at $18.61. Atara Biotherapeutics News: This is the News-site for the company Atara Biotherapeutics on Markets Insider. Volume today is light. The firm has a market cap of $1.53 billion, a price-to-earnings ratio of -4.25 and a beta of 2.78. It focuses on developing therapeutics for patients with serious life-threatening such as cancer, autoimmune and other viral diseases. Atara Biotherapeutics currently has 2 hold ratings and 8 buy ratings from Wall Street analysts. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. A "buy" rating indicates that analysts believe ATRA will outperform the market and that investors should add to their positions of Atara Biotherapeutics. Get Stock & Bond Quotes, Trade Prices, Charts, Financials and Company News & Information for OTCQX, OTCQB and Pink Securities. Atara Biotherapeutics, Inc. (NASDAQ:ATRA) CFO Utpal Koppikar sold 5,820 shares of Atara Biotherapeutics stock in a transaction dated Tuesday, June 8th. The new note on the price target was released on June 30, 2020, representing the official price target for Atara Biotherapeutics Inc. stock. Atara Biotherap (ATRA) Atara Biotherap. Find real-time ATRA - Atara Biotherapeutics Inc stock quotes, company profile, news and forecasts from CNN Business. SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T- cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases, today announced the pricing of an underwritten public offering of 5,102,041 shares of its common stock … Atara Biotherapeutics Inc (ATRA) stock is trading at $13.82 as of 11:53 AM on Wednesday, May 5, a rise of $0.17, or 1.25% from the previous closing price of $13.65. About Atara Biotherapeutics, Inc. The stock has a consensus analyst rating of "Buy." ATRA Atara Biotherapeutics Inc Latest News. Wall Street brokerages predict that Atara Biotherapeutics, Inc. (NASDAQ:ATRA) will post ($0.93) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Atara Biotherapeutics news and ATRA price. Zacks. Get the latest Atara Biotherapeutics Inc (ATRA) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Atara Biotherapeutics Inc Change company Symbol lookup 02/18/2021 04:01:00 PM. Atara Biotherapeutics Inc. (NASDAQ: ATRA) is -30.51% lower on its value in year-to-date trading and has touched a low of $7.45 and a high of $28.20 in the current 52-week trading range. Press Release reported on 04/02/21 that Atara Biotherapeutics … Atara Biotherapeutics upgraded to overweight from neutral at J.P. Morgan MarketWatch. In connection with the proposed offering, Atara Biotherapeutics expects to grant the underwriters a 30-day option to purchase up to an additional $22,500,000 of shares of its common stock at the public offering price, less the underwriting discounts and commissions. The company report on January 11, 2021 that Atara Biotherapeutics Will Present Recent Advancements and Key Upcoming Milestones at the 39th Annual J.P. Morga The stock, one that is focused in the biotech space, is currently trading at $11.35 after tumbling -7.72% so far today.… A look at the stock Atara Biotherapeutics (ATRA) in Focus: Stock Moves 6.9% Higher by Zacks Equity Research Published on September 26,2018 Atara Biotherapeutics (ATRA) saw a … Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease, today reported the grant of an aggregate of 52,019 restricted stock units of Atara’s common stock … Two analysts have provided estimates for Atara Biotherapeutics’ earnings, with the lowest EPS estimate coming in at ($1.05) and the highest estimate coming in at ($0.82). Citigroup, Cowen and Evercore ISI are acting as joint book-running managers for the offering. Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 (C) (4) SOUTH SAN FRANCISCO, Calif.-- (BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: … View the latest ratings for ATRA. Atara Biotherapeutics, Inc. is currently approximately $ 13.56 per share. The analysts price targets range from a … Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with severe diseases including solid tumors, hematologic cancers and autoimmune diseases, today announced that it has commenced an underwritten public offering of shares of its common stock … Get news for Nasdaq companies quoted on the stock market, press releases, financial disclosures and multimedia content, for investment community, individual investors and the general public. Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of an aggregate of 140,861 restricted stock units of Atara… ATRA / Atara Biotherapeutics, Inc. / Redmile Group, LLC - SC 13G/A Passive Investment. ATRA Atara Biotherapeutics Inc Latest News. Atara Biotherapeutics Stock Falls After Goldman Downgrade. Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Apr 02, 2021 4:35pm EDT Atara Biotherapeutics Presents New Long-Term Overall Survival Data from a Combined Analysis of Phase 2 Tab-cel® Studies for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease at The EBMT 2021 Annual Meeting Atara Biotherapeutics stock was originally listed at a price of $10.65 in Oct 16, 2014. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. The company’s stock price has collected 5.13% of gains in the last five trading sessions. View today's stock price, news and analysis for Atara Biotherapeutics Inc. (ATRA). ATRA | Complete Atara Biotherapeutics Inc. stock news by MarketWatch. 5Y. also delivers off-the-shelf treatments to patients with high unmet medical need. At Atara, our mission is to transform the lives of patients with serious diseases through pioneering science, teamwork and a commitment to excellence. We aim to offer hope to people whose lives have been impacted by cancer and autoimmune diseases. OTCIQ. Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. also delivers off-the-shelf treatments to patients with high unmet medical need. Atara Biotherapeutics, Inc. (NASDAQ:ATRA) price on Wednesday, Apr 21, rose 2.63% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $13.64.
Uksf Medical Support Unit, Kuwait Gdp Growth Rate 2019, Camp As Sayliyah Website, Constrict Crossword Clue 5 Letters, Maypole Dancing Australia, Pathfinder: Kingmaker Druid Wild Shape Build, Georgia Tech Regular Decision Date 2021,
Leave a Reply